WO2020111087A9 - 複素環化合物 - Google Patents
複素環化合物 Download PDFInfo
- Publication number
- WO2020111087A9 WO2020111087A9 PCT/JP2019/046261 JP2019046261W WO2020111087A9 WO 2020111087 A9 WO2020111087 A9 WO 2020111087A9 JP 2019046261 W JP2019046261 W JP 2019046261W WO 2020111087 A9 WO2020111087 A9 WO 2020111087A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heterocyclic compound
- compound
- cocrystal
- solvate
- prophylactic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101150113681 MALT1 gene Proteins 0.000 abstract 1
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 abstract 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940043274 prophylactic drug Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217019537A KR102359143B1 (ko) | 2018-11-28 | 2019-11-27 | 헤테로시클릭 화합물 |
KR1020227003334A KR102646470B1 (ko) | 2018-11-28 | 2019-11-27 | 헤테로시클릭 화합물 |
EP19890558.0A EP3888652A4 (en) | 2018-11-28 | 2019-11-27 | HETEROCYCLIC COMPOUND |
SG11202105652XA SG11202105652XA (en) | 2018-11-28 | 2019-11-27 | Heterocyclic compound |
CN201980078144.XA CN113038948B (zh) | 2018-11-28 | 2019-11-27 | 杂环化合物 |
IL303962A IL303962A (en) | 2018-11-28 | 2019-11-27 | The tricyclic compound |
AU2019390863A AU2019390863A1 (en) | 2018-11-28 | 2019-11-27 | Heterocyclic compound |
US17/296,434 US20220048916A1 (en) | 2018-11-28 | 2019-11-27 | Heterocyclic compound |
CA3120774A CA3120774A1 (en) | 2018-11-28 | 2019-11-27 | Heterocyclic compound |
JP2020557754A JP6972384B2 (ja) | 2018-11-28 | 2019-11-27 | 複素環化合物 |
MX2021005877A MX2021005877A (es) | 2018-11-28 | 2019-11-27 | Compuesto heterociclico. |
BR112021009994-8A BR112021009994A2 (pt) | 2018-11-28 | 2019-11-27 | composto, e, medicamento |
IL283368A IL283368A (en) | 2018-11-28 | 2021-05-23 | The tricyclic compound |
PH12021551251A PH12021551251A1 (en) | 2018-11-28 | 2021-05-28 | Heterocyclic compound |
ZA2021/04402A ZA202104402B (en) | 2018-11-28 | 2021-06-25 | Heterocyclic compound |
US17/367,171 US11230545B2 (en) | 2018-11-28 | 2021-07-02 | Heterocyclic compound |
JP2021179627A JP7434249B2 (ja) | 2018-11-28 | 2021-11-02 | 複素環化合物 |
US17/528,677 US11897879B2 (en) | 2018-11-28 | 2021-11-17 | Heterocyclic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-222530 | 2018-11-28 | ||
JP2018222530 | 2018-11-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/296,434 A-371-Of-International US20220048916A1 (en) | 2018-11-28 | 2019-11-27 | Heterocyclic compound |
US17/367,171 Continuation US11230545B2 (en) | 2018-11-28 | 2021-07-02 | Heterocyclic compound |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020111087A1 WO2020111087A1 (ja) | 2020-06-04 |
WO2020111087A9 true WO2020111087A9 (ja) | 2021-01-21 |
Family
ID=70853784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/046261 WO2020111087A1 (ja) | 2018-11-28 | 2019-11-27 | 複素環化合物 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20220048916A1 (ja) |
EP (1) | EP3888652A4 (ja) |
JP (2) | JP6972384B2 (ja) |
KR (2) | KR102646470B1 (ja) |
CN (1) | CN113038948B (ja) |
AU (1) | AU2019390863A1 (ja) |
BR (1) | BR112021009994A2 (ja) |
CA (1) | CA3120774A1 (ja) |
IL (2) | IL303962A (ja) |
MX (1) | MX2021005877A (ja) |
PH (1) | PH12021551251A1 (ja) |
SG (1) | SG11202105652XA (ja) |
TW (1) | TWI784213B (ja) |
WO (1) | WO2020111087A1 (ja) |
ZA (1) | ZA202104402B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220048916A1 (en) * | 2018-11-28 | 2022-02-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20230192685A1 (en) | 2020-05-27 | 2023-06-22 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
TW202342032A (zh) * | 2022-02-02 | 2023-11-01 | 日商小野藥品工業股份有限公司 | 含有malt1抑制劑作為有效成分的癌治療劑 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2288521A1 (fr) * | 1974-10-25 | 1976-05-21 | Merck Patent Gmbh | Nouvelles penicillines et procede pour leur preparation |
AU699091B2 (en) * | 1995-05-31 | 1998-11-19 | Dainippon Sumitomo Pharma Co., Ltd. | Novel naphthyridine derivatives |
GB9720052D0 (en) * | 1997-09-19 | 1997-11-19 | Smithkline Beecham Plc | Novel compounds |
GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
PT3149001T (pt) | 2014-05-28 | 2019-07-25 | Novartis Ag | Novos derivados de pirazolee pirimidina e seu uso como inibidores de malt1 |
KR20180080311A (ko) | 2015-11-13 | 2018-07-11 | 노파르티스 아게 | 신규 피라졸로 피리미딘 유도체 |
SG11201900745VA (en) | 2016-07-29 | 2019-02-27 | Lupin Ltd | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
WO2018085247A1 (en) | 2016-11-01 | 2018-05-11 | Cornell University | Compounds for malt1 degradation |
WO2018165385A1 (en) * | 2017-03-08 | 2018-09-13 | Cornell University | Inhibitors of malt1 and uses thereof |
US20200111087A1 (en) * | 2018-10-08 | 2020-04-09 | Jinlei Zhou | Method for encrypting digital contract document between contractors |
US20220048916A1 (en) * | 2018-11-28 | 2022-02-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2019
- 2019-11-27 US US17/296,434 patent/US20220048916A1/en active Pending
- 2019-11-27 AU AU2019390863A patent/AU2019390863A1/en active Pending
- 2019-11-27 KR KR1020227003334A patent/KR102646470B1/ko active IP Right Grant
- 2019-11-27 JP JP2020557754A patent/JP6972384B2/ja active Active
- 2019-11-27 IL IL303962A patent/IL303962A/en unknown
- 2019-11-27 KR KR1020217019537A patent/KR102359143B1/ko active IP Right Grant
- 2019-11-27 CA CA3120774A patent/CA3120774A1/en active Pending
- 2019-11-27 TW TW108143201A patent/TWI784213B/zh active
- 2019-11-27 EP EP19890558.0A patent/EP3888652A4/en active Pending
- 2019-11-27 WO PCT/JP2019/046261 patent/WO2020111087A1/ja unknown
- 2019-11-27 CN CN201980078144.XA patent/CN113038948B/zh active Active
- 2019-11-27 MX MX2021005877A patent/MX2021005877A/es unknown
- 2019-11-27 SG SG11202105652XA patent/SG11202105652XA/en unknown
- 2019-11-27 BR BR112021009994-8A patent/BR112021009994A2/pt unknown
-
2021
- 2021-05-23 IL IL283368A patent/IL283368A/en unknown
- 2021-05-28 PH PH12021551251A patent/PH12021551251A1/en unknown
- 2021-06-25 ZA ZA2021/04402A patent/ZA202104402B/en unknown
- 2021-07-02 US US17/367,171 patent/US11230545B2/en active Active
- 2021-11-02 JP JP2021179627A patent/JP7434249B2/ja active Active
- 2021-11-17 US US17/528,677 patent/US11897879B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11897879B2 (en) | 2024-02-13 |
KR20210092301A (ko) | 2021-07-23 |
WO2020111087A1 (ja) | 2020-06-04 |
SG11202105652XA (en) | 2021-06-29 |
IL303962A (en) | 2023-08-01 |
JP6972384B2 (ja) | 2021-11-24 |
TW202039484A (zh) | 2020-11-01 |
US20220089595A1 (en) | 2022-03-24 |
JPWO2020111087A1 (ja) | 2021-09-27 |
KR102359143B1 (ko) | 2022-02-08 |
JP7434249B2 (ja) | 2024-02-20 |
US20210332045A1 (en) | 2021-10-28 |
EP3888652A4 (en) | 2022-10-19 |
MX2021005877A (es) | 2021-07-16 |
CN113038948A (zh) | 2021-06-25 |
AU2019390863A1 (en) | 2021-06-24 |
KR20220019848A (ko) | 2022-02-17 |
US11230545B2 (en) | 2022-01-25 |
ZA202104402B (en) | 2023-01-25 |
BR112021009994A2 (pt) | 2021-08-17 |
TW202306956A (zh) | 2023-02-16 |
CA3120774A1 (en) | 2020-06-04 |
IL283368A (en) | 2021-07-29 |
CN113038948B (zh) | 2024-07-12 |
US20220048916A1 (en) | 2022-02-17 |
TWI784213B (zh) | 2022-11-21 |
EP3888652A1 (en) | 2021-10-06 |
JP2022017461A (ja) | 2022-01-25 |
AU2019390863A2 (en) | 2021-07-01 |
PH12021551251A1 (en) | 2021-12-06 |
KR102646470B1 (ko) | 2024-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020111087A9 (ja) | 複素環化合物 | |
PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
WO2017035353A8 (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | |
PH12020551305A1 (en) | Pharmaceutical Compounds | |
JOP20210001A1 (ar) | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 | |
CA2983481A1 (en) | Janus kinase inhibitor | |
MY174821A (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
WO2019178191A8 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
EA201990833A1 (ru) | Соединение пиридина | |
MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
CA2914620C (en) | Heterocyclic derivatives and use thereof | |
AU2015211852A1 (en) | Heterocyclic sulfonamide derivative and medicine comprising same | |
WO2015000431A9 (zh) | 替唑尼特氨基甲酸酯及其在药学中的应用 | |
ZA202307945B (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
AU2018246053A8 (en) | IP6K inhibitors | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2021007247A (es) | Derivados de rapamicina. | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
MX2019011182A (es) | Combinacion de derivados de isoindolinona con sgi-110. | |
PH12019502509A1 (en) | Compounds and methods for treating bacterial infections | |
WO2019195641A3 (en) | 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same | |
MX2022005951A (es) | Compuestos de pirrolotriazina que actuan como inhibidor de mnk. | |
AU2019408336A8 (en) | Phenylpyrrolidine compound and use thereof | |
WO2019217933A8 (en) | Inhibitors of the ras oncoprotein, methods of making and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19890558 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020557754 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3120774 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021009994 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20217019537 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019390863 Country of ref document: AU Date of ref document: 20191127 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019890558 Country of ref document: EP Effective date: 20210628 |
|
ENP | Entry into the national phase |
Ref document number: 112021009994 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210524 |